Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates

Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients Treated at end of 2018 -...
February 26, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia

New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and...
February 25, 2019 04:00 ET | Source: Amicus Therapeutics, Inc.

U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease

First BTD Granted for a Second Generation Lysosomal Storage Disorder Therapy First BTD for an Investigational Treatment in Pompe Disease CRANBURY, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Amicus...
February 12, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019

CRANBURY, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28,...
February 05, 2019 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue for both ERT-Naïve and ERT-Switch Patients Patient Reported Outcomes Data...
January 18, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019

CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...
January 07, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance

Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance 2019 Galafold Revenue Expected to Nearly Double – with Guidance of $160M-$180M Pompe Phase 3 PROPEL Study Expected to Complete...
January 03, 2019 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at...
January 03, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease

Second Gene Therapy to Enter Clinic at Nationwide Children’s Hospital for Neurologic Lysosomal Storage Disorders Initial Safety is Encouraging with No Serious Adverse Events at One Month CRANBURY,...
December 20, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease

CRANBURY, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...